To determine whether we could counteract anti-spike-induced immune activation, we blocked Syk using R406, the active component of the small molecule inhibitor fostamatinib, an FDA- and EMA-approved drug for treatment of immune thrombocytopenia (ITP) (37). This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.